FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/01/079750 [Registered on: 29/01/2025] Trial Registered Prospectively
Last Modified On: 19/12/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Preventive
Process of Care Changes 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Does periprocedural antibiotic prevent micturating cystourethrography (MCU) associated urinary tract infection in children?  
Scientific Title of Study   Periprocedural antibiotic prophylaxis compared to placebo in preventing voiding cystourethrography-associated urinary tract infection in children- A randomized controlled trial 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Preeti Talli 
Designation  Junior resident 
Affiliation  Jawaharlal Institute of Post graduate Medical Education and Research (JIPMER) 
Address  Department of Paediatrics, 2nd floor, Women and Child block, JIPMER, Dhanvantari nagar, Puducherry- 605006 India

Pondicherry
PONDICHERRY
605006
India 
Phone  9901136238  
Fax    
Email  pretally2@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Sudarsan K 
Designation  Assistant Professor 
Affiliation  Jawaharlal Institute of Post graduate Medical Education and Research (JIPMER) 
Address  Department of Paediatrics, 2nd floor, Women and Child block, JIPMER, Dhanvantari nagar, Puducherry- 605006 India

Pondicherry
PONDICHERRY
605006
India 
Phone  9855071507  
Fax    
Email  sudarsanjipmer@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Sudarsan K 
Designation  Assistant Professor 
Affiliation  Jawaharlal Institute of Post graduate Medical Education and Research (JIPMER) 
Address  Department of Paediatrics, 2nd floor, Women and Child block, JIPMER, Dhanvantari nagar, Puducherry- 605006 India

Pondicherry
PONDICHERRY
605006
India 
Phone  9855071507  
Fax    
Email  sudarsanjipmer@gmail.com  
 
Source of Monetary or Material Support  
JIPMER Intramural Research Fund (IMRF), JIPMER, Puducherry- 605006 
 
Primary Sponsor  
Name  Jawaharlal Institute of Post graduate Medical Education and Research, JIPMER 
Address  Dhanavantri nagar, Pondicherry- 605006 India  
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Preeti Talli  Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)  Pediatric Nephrology services, Department of Pediatrics, Women and Child Health block, JIPMER, Dhanavantri nagar, Pondicherry - 605006
Pondicherry
PONDICHERRY 
9901136238

pretally2@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
JIPMER Institutional Ethics Committee- Interventional Studies  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: N390||Urinary tract infection, site notspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Peri-procedural Antibiotics (Co- trimoxazole)   one randomized group of patients undergoing voiding cystourethrography receiving antibiotic Co-trimoxazole at 2 mg/Kg (Syrup Bactrim (40 mg/5 ml) at 0.25 ml/kg) in 2 divided doses- first dose 30-60 minutes prior to the procedure and the second dose 4-8 hours post-procedure 
Comparator Agent  Placebo group  The other randomized group of patients undergoing Voiding cystourethrography receiving placebo at 0.25 ml/kg in 2 divided doses- first dose 30-60 minutes prior to the procedure and the second dose 4-8 hours post procedure 
 
Inclusion Criteria  
Age From  3.00 Month(s)
Age To  18.00 Year(s)
Gender  Both 
Details  Children aged 3 months to 18 years undergoing voiding cystourethrography 
 
ExclusionCriteria 
Details  1) Children on immunosuppressive medications like nephrotic syndrome or post kidney transplant recipients
2) Children with known allergy to cotrimoxazole/ radiocontrast agent or sulpha allergy
3) Patient who already has an indwelling urinary catheter on the day of voiding cystourethrography
4) Child having fever and/or signs and symptoms of urinary tract infection on the scheduled day of voiding cystourethrography 
 
Method of Generating Random Sequence   Stratified block randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded 
Primary Outcome  
Outcome  TimePoints 
To compare the proportion of patients who develop symptomatic voiding cystourethrography-associated urinary tract infection within 7 days post procedure between the antibiotic prophylaxis group and placebo group in children aged 3 months to 18 years undergoing voiding cystourethrography  Within 7 days post voiding cystourethrography 
 
Secondary Outcome  
Outcome  TimePoints 
To compare the proportion of patients who have asymptomatic bacteriuria between days 2-7 post voiding cystourethrography in the antibiotic prophylaxis and placebo groups.
To compare the proportion of patients who develop symptomatic voiding cystourethrography-associated urinary tract infection between 7-14 days post procedure between the antibiotic prophylaxis group and placebo group
To determine the antibiotic sensitivity pattern in these children.
To identify the risk factors for developing post-voiding cystourethrography-associated urinary tract infection. 
2-14 days post voiding cystourethrography 
 
Target Sample Size   Total Sample Size="208"
Sample Size from India="208" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3/ Phase 4 
Date of First Enrollment (India)   10/02/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

The study shall be undertaken at the Department of Pediatrics, JIPMER from Jan 2025 for a period of 2 years after acquiring the Institutional Ethics Committee (IEC) clearance and CTRI registration prior to enrolment of the first patient. This study shall include patients aged 3 months to 18 years undergoing VCUG. When these patients come to the hospital for VCUG (absence of signs/symptoms of UTI at the time of presentation and a negative urine culture within the preceding 2 weeks are mandatory to undertake the test), they will be approached for possible enrollment into the trial. Written informed consent will be taken from the parents of the study participants (and assent from children 8 years or older) and the study will be conducted in accordance with the Declaration of Helsinki.  

Once the patients are enrolled, they will be randomly allocated to group A or group B based on which they will either receive antibiotic or placebo. The children already on antibiotic prophylaxis will be stratified and then allocated to group A  or group B. The subjects will receive one dose of the drug (antibiotic/placebo) 30-60 minutes prior to the procedure and the second dose 4-8 hours after the procedure. VCUG will be performed under strict aseptic precautions as per standard protocols being followed in the radiology department of the institute. On the evening of the procedure, a telephonic call will be made to all the enrolled participants to enquire about development of any signs/ symptoms of UTI and if the child has taken the evening dose of the medicine (antibiotic/ placebo).

Subsequently, all enrolled patients will be followed up for development of UTI over the next 7 days (considering the day of VCUG as day 1). Urine sample of those patients who present with signs and symptoms of urinary tract infection within 7 days post-VCUG will be collected and sent for urine routine and culture. They will be admitted in the Pediatrics ward and administered parenteral antibiotics as per ISPN 2023 guidelines.

If patients do not develop signs/symptoms of UTI, they will undergo urine routine and culture testing to look for prevalence of asymptomatic bacteriuria and identify antibiotic sensitivity pattern.

Ad per current practice, patients report to the pediatric nephrology clinic 2-7 days after VCUG to interpret the findings of VCUG and make further management decisions. If patients do not report to the pediatric nephrology clinic by day 5 post VCUG, a telephonic reminder will be sent to them apart from enquiring about the signs and symptoms of UTI that might have developed post VCUG.


 


 
Close